Arsenic trioxide as intravascular or oral agent used in patients with Acute promyelocytic leukemia
Phase 1
- Conditions
- Acute promyelocytic leukemia.Acute promyelocytic leukemia
- Registration Number
- IRCT138710271030N4
- Lead Sponsor
- Hematology-Oncology & SCT Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Inclusion Criteria: Acute promyelocytic leukemia type M3, complete remission, not receiving any marine foods during last week, normal cardiopulmonary and renal function.
Exclusion Criteria
Less than 16 years old, Impaired cardiopulmonary and renal function.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of arsenic trioxide. Timepoint: 0,1,2,3,4,6,8,24,25,26,27,28,30,32,48h after initiation of therapy. Method of measurement: Atomic Absorption of Arsenic.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: During the study. Method of measurement: History taking and physical examination.